Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lifecare AS ( (DE:LFC0) ) just unveiled an update.
Lifecare ASA has announced significant progress in its development of Continuous Glucose Monitoring (CGM) systems, achieving a design freeze for first-in-human trials and preparing for a veterinary launch. The company has received ethical approval for its first-in-human trials and is working towards CE marking, with plans to reach market readiness by the end of 2026. Lifecare successfully raised funds through warrant exercises but will require further capital to continue its development and market entry. This advancement positions Lifecare as a key player in the diabetes technology industry, with potential implications for stakeholders as it seeks additional investment to sustain its momentum.
More about Lifecare AS
Lifecare ASA is a clinical stage medical sensor company based in Norway, focusing on developing next-generation Continuous Glucose Monitoring (CGM) systems. The company aims to improve diabetes management for both humans and pets by utilizing innovative sensor technology suitable for monitoring various body analytes.
Average Trading Volume: 279,806
Current Market Cap: NOK293.5M
For an in-depth examination of LFC0 stock, go to TipRanks’ Overview page.